TOP TEN perturbations for 1552319_a_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1552319_a_at
Selected probe(set): 1552319_a_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1552319_a_at (1552319_a_at) across 6673 perturbations tested by GENEVESTIGATOR:

psoriasis study 11 (lesional; brodalumab; 15d; 700mg) / psoriasis study 11 (lesional; baseline)

Relative Expression (log2-ratio):-3.2962961
Number of Samples:8 / 25
Experimental psoriasis study 11 (lesional; brodalumab; 15d; 700mg)
Lesional skin punch biopsies derived from patients with moderate to severe plaque psoriasis at day 15 (week 2) after treatment with a single dose (700 mg i.v.) of brodalumab. ATC code:
Control psoriasis study 11 (lesional; baseline)
Lesional skin punch biopsy samples derived from patients with moderate to severe plaque psoriasis before treatment.

transwell differentiation study 1 (TEER base) / untreated MCF10A cell sample

Relative Expression (log2-ratio):3.0606394
Number of Samples:3 / 3
Experimental transwell differentiation study 1 (TEER base)
MCF10A cells were plated onto polyester permeable supports (Transwells) at a density of 10^5 cells/cm^2. Base represents those plates with a low trans-epithelial electrical resistance (TEER) of 200-300 Ohms x cm^2.
Control untreated MCF10A cell sample
MCF10A cells grown to confluency on sterile plastic.

transwell differentiation study 1 (TEER mid) / untreated MCF10A cell sample

Relative Expression (log2-ratio):3.040348
Number of Samples:3 / 3
Experimental transwell differentiation study 1 (TEER mid)
MCF10A cells were plated onto polyester permeable supports (Transwells) at a density of 10^5 cells/cm^2. Midpoint represents those plates with a mid trans-epithelial electrical resistance (TEER) of 1400-1600 Ohms x cm^2.
Control untreated MCF10A cell sample
MCF10A cells grown to confluency on sterile plastic.

transwell differentiation study 1 (TEER plateau) / untreated MCF10A cell sample

Relative Expression (log2-ratio):2.97863
Number of Samples:4 / 3
Experimental transwell differentiation study 1 (TEER plateau)
MCF10A cells were plated onto polyester permeable supports (Transwells) at a density of 10^5 cells/cm^2. Plateau represents those plates with a plateau trans-epithelial electrical resistance (TEER) of 3000-3200 Ohms x cm^2.
Control untreated MCF10A cell sample
MCF10A cells grown to confluency on sterile plastic.

expO ovary cancer study 1 (mucinous adenocarcinoma; primary) / expO ovary cancer study 1 (carcinoma, NOS; primary)

Relative Expression (log2-ratio):-2.9166012
Number of Samples:6 / 2
Experimental expO ovary cancer study 1 (mucinous adenocarcinoma; primary)
Primary tumor tissue samples obtained from the ovary of patients with mucinous adenocarcinoma.
Control expO ovary cancer study 1 (carcinoma, NOS; primary)
Primary tumor tissue samples obtained from the ovary of patients with carcinoma (NOS).

ovarian tumor study 30 (PDX; serous cystadenocarcinoma, NOS; primary) / ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary)

Relative Expression (log2-ratio):2.8139935
Number of Samples:13 / 2
Experimental ovarian tumor study 30 (PDX; serous cystadenocarcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary serous cystadenocarcinoma, NOS of the ovary (subcutaneously implanted).
Control ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary adenocarcinoma, NOS of the ovary (subcutaneously implanted).

expO ovary cancer study 1 (malignant mixed Mullerian tumor; primary) / expO ovary cancer study 1 (carcinoma, NOS; primary)

Relative Expression (log2-ratio):-2.773798
Number of Samples:3 / 2
Experimental expO ovary cancer study 1 (malignant mixed Mullerian tumor; primary)
Primary tumor tissue samples obtained from the ovary of patients with malignant mixed Mullerian tumor.
Control expO ovary cancer study 1 (carcinoma, NOS; primary)
Primary tumor tissue samples obtained from the ovary of patients with carcinoma (NOS).

skin transplantation study 1 (7d) / split-thickness skin grafting study 1

Relative Expression (log2-ratio):2.6791124
Number of Samples:5 / 6
Experimental skin transplantation study 1 (7d)
Human skin punch biopsy from patients after skin grafting. Sample was taken at the site of re-epithelialization 7 days after surgery.
Control split-thickness skin grafting study 1
Skin punch biopsy from patients with skin injury (burn injury, congelation, wound, compartment syndrome) immediately after split-thickness skin grafting was done. Sample was taken from the acute wound after grafting.

melanoma study 34 (metastatic) / melanoma study 34 (in situ)

Relative Expression (log2-ratio):-2.6489916
Number of Samples:40 / 2
Experimental melanoma study 34 (metastatic)
Metastatic tumor tissue sample obtained from the patients with metastatic malignant melanoma of the skin. Metastatic samples composed of 22 macroscopic lymph node metastases, 16 subcutaneous metastases and 2 solid organ metastases (adrenal and brain).
Control melanoma study 34 (in situ)
Tumor tissue from the skin of patients with melanoma in situ.

ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary) / ovarian tumor study 30 (PDX; serous cystadenocarcinoma, NOS; primary)

Relative Expression (log2-ratio):-2.6098232
Number of Samples:2 / 13
Experimental ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary transitional cell carcinoma, NOS of the ovary (subcutaneously implanted).
Control ovarian tumor study 30 (PDX; serous cystadenocarcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary serous cystadenocarcinoma, NOS of the ovary (subcutaneously implanted).